[1] [1] RAHIB L, SMITH B D, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States［J］. Cancer Research, 2014, 74(11): 2913-2921.

[2] [2] KONGURE N, YOKOBORI T, OGATA K, et al. Low expression of MCM2, MCM4, MCM10 is associated with gastric cancer progression and poor prognosis［J］. Anticancer Research, 2017, 37(1): 191-196.

[3] [3] CHEN X, SAHASRABUDDHE A A, SZANKASI P, et al. MCM2, MCM4, MCM10-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival［J］. Cell Death Differentiation, 2014, 21(10): 1535-1545.

[4] [4] DRAUS T, ANSARI D,WIKSTROM F, et al. Projected economic burden of pancreatic cancer in Sweden in 2030［J］. Acta Oncologica, 2021, 60(7): 866-871.

[5] [5] CARIOLI G, MALVEZZI M, BERTUCCIO P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer［J］. Ann of Oncology, 2021, 32(4): 478-487.

[6] [6] GROSSBERG A J, CHU L C, DEUG C R, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma［J］. CA: A Cancer Journal for Clinicians, 2020, 70(5): 375-403.

[7] [7] CHEN W, ZHENG R, BAADE P, et al. Cancer statistics in China, 2015［J］. CA: A Cancer Journal for Clinicians, 2016, 66(2): 115-132.

[8] [8] LI Z, XU X Z. Post-translational modifications of the mini-chromosome maintenance proteins in DNA replication［J］. Genes Basel, 2019, 10(5): E331.

[9] [9] LIU Z, LI J, CHEN J, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression［J］. BMC Cancer, 2018, 18(1): 200.

[10] [10] KRISTENSEN T P, REEJA M C, GRAY F C, et al. The haloarchaeal MCM proteins: bioinformatic analysis and targeted mutagenesis of the β7-β8 and β9-β10 hairpin loops and conserved zinc binding domain cysteines［J］. Frontiers in Microbiology, 2014, 5(26): 123-135.

[11] [11] YANG Y, MA S, YE Z, et al. MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway［J］. Journal of Cellular Biochemistry, 2020, 121(2): 1283-1294.

[12] [12] BROSH R M Jr, TRAKSELIS M A. Fine-tuning of the replisome: Mcm10 regulates fork progression and regression［J］. Cell Cycle, 2019, 18(10): 1047-1055.

[13] [13] DAS M, PRASAD S B, YADAV S S, et al. Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis［J］. PLoS One, 2013, 8(7): e69607.

[14] [14] PENG Y P, ZHU Y, YIN L D, et al. The expression and prognostic roles of MCMs in pancreatic cancer［J］. PLoS One, 2016, 11(10): e0164150.

[15] [15] YU S, WANG G, HI Y, et al. MCMs in cancer: prognostic potential and mechanisms［J］. Analytical Cellular Pathology, 2020, 2020(9): 1-11.

[16] [16] CHEN X L, ZHOU W X, LIANG C, et al. Codelivery nanosystem targeting the deep microenvironment of pancreatic cancer［J］. Nano Letters, 2019, 19(6): 3527-3534.

[17] [17] HO W J, JAFFEE E M, ZHENG L. The tumour microenvironment in pancreatic cancer－clinical challenges and opportunities［J］. Nature Reviews Clinical Oncology, 2020, 17(9): 527-540.

[18] [18] YANG S, SUN B, KONG R. Progress in the relationship between chemotherapy resistance and tumor microenvironment in pancreatic cancer ［J］. Chinese Journal of Pancreatopathy, 2018, 18(5): 356-359.

[19] [19] VICTORIA L, ROY M, SUSAN M, et al. Suppression of reserve MCM complexes chemosensitizes to gemcitabine and 5-fluorouracil［J］. Molecular Cancer Research, 2015, 13(9): 1296-1305.